CL2008000434A1 - Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros. - Google Patents
Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.Info
- Publication number
- CL2008000434A1 CL2008000434A1 CL200800434A CL2008000434A CL2008000434A1 CL 2008000434 A1 CL2008000434 A1 CL 2008000434A1 CL 200800434 A CL200800434 A CL 200800434A CL 2008000434 A CL2008000434 A CL 2008000434A CL 2008000434 A1 CL2008000434 A1 CL 2008000434A1
- Authority
- CL
- Chile
- Prior art keywords
- oxazolinas
- anxiety
- depression
- diseases
- stress
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title 1
- 208000020925 Bipolar disease Diseases 0.000 title 1
- 230000036506 anxiety Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000008569 process Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/28—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07102429 | 2007-02-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2008000434A1 true CL2008000434A1 (es) | 2008-08-22 |
Family
ID=39577660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200800434A CL2008000434A1 (es) | 2007-02-15 | 2008-02-12 | Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7902238B2 (es) |
| EP (1) | EP2121641B1 (es) |
| JP (1) | JP5130305B2 (es) |
| KR (2) | KR101335845B1 (es) |
| CN (1) | CN101616902B (es) |
| AR (1) | AR065322A1 (es) |
| AU (1) | AU2008214774A1 (es) |
| BR (1) | BRPI0807813A2 (es) |
| CA (1) | CA2676944C (es) |
| CL (1) | CL2008000434A1 (es) |
| ES (1) | ES2525229T3 (es) |
| IL (1) | IL200045A0 (es) |
| MX (1) | MX2009008465A (es) |
| PE (1) | PE20081783A1 (es) |
| RU (1) | RU2460725C2 (es) |
| TW (1) | TWI372051B (es) |
| WO (1) | WO2008098857A1 (es) |
| ZA (1) | ZA200905272B (es) |
Families Citing this family (142)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101052122B1 (ko) | 2005-10-25 | 2011-07-26 | 시오노기세야쿠 가부시키가이샤 | 아미노디히드로티아진 유도체 |
| US8841334B2 (en) * | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
| EP2038266A2 (en) * | 2006-05-31 | 2009-03-25 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
| MX2008015214A (es) * | 2006-05-31 | 2008-12-12 | Abbott Lab | Compuestos como ligandos de receptor canabinoide y sus usos. |
| CN101765594A (zh) | 2007-03-28 | 2010-06-30 | 雅培制药有限公司 | 作为大麻素受体配体的1,3-噻唑-2(3h)-亚基化合物 |
| US8501794B2 (en) * | 2007-04-17 | 2013-08-06 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| US7872033B2 (en) * | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| EP2147914B1 (en) | 2007-04-24 | 2014-06-04 | Shionogi&Co., Ltd. | Aminodihydrothiazine derivatives substituted with cyclic groups |
| MX2009012374A (es) * | 2007-05-18 | 2009-12-01 | Abbott Lab | Compuestos novedosos como ligandos del receptor de canabinoides. |
| KR101133862B1 (ko) * | 2007-07-27 | 2012-04-06 | 에프. 호프만-라 로슈 아게 | Ｔａａｒ 리간드로서의 2-아제티딘메테인아민 및 2-피롤리딘메테인아민 |
| US9193713B2 (en) * | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| CA2716857A1 (en) * | 2008-03-11 | 2009-09-17 | Teodozyi Kolasa | Novel compounds as cannabinoid receptor ligands |
| WO2009121872A2 (en) | 2008-04-01 | 2009-10-08 | Abbott Gmbh & Co. Kg | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy |
| MX2010013256A (es) * | 2008-06-13 | 2010-12-21 | Shionogi & Co | Derivado heterociclico que contiene azufre que tiene actividad inhibitoria de beta-secretasa. |
| US8242153B2 (en) * | 2008-07-24 | 2012-08-14 | Hoffmann-La Roche Inc. | 4,5-dihydro-oxazol-2YL derivatives |
| CA2731095A1 (en) * | 2008-08-05 | 2010-02-11 | Abbott Laboratories | Compounds useful as inhibitors of protein kinases |
| MX2011001755A (es) * | 2008-08-15 | 2011-03-24 | Abbott Lab | Derivados de imina como ligandos de receptor canabinoide. |
| US8846730B2 (en) * | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| US8859596B2 (en) | 2008-09-16 | 2014-10-14 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| CN102186845B (zh) | 2008-10-17 | 2016-09-07 | 阿卡制药有限公司 | S1p受体调节剂以及它们的用途 |
| EP2344446A4 (en) | 2008-10-17 | 2012-04-04 | Akaal Pharma Pty Ltd | S1P RECEPTOR MODULATORS |
| JP2012505908A (ja) * | 2008-10-17 | 2012-03-08 | アボット・ラボラトリーズ | Ｔｒｐｖ１アンタゴニスト |
| TW201020236A (en) * | 2008-10-17 | 2010-06-01 | Abbott Lab | TRPV1 antagonists |
| JPWO2010047372A1 (ja) * | 2008-10-22 | 2012-03-22 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体 |
| UA108193C2 (uk) | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP3666758A1 (en) | 2008-12-05 | 2020-06-17 | AbbVie Inc. | Process for the preparation of a sulfonamide derivative |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| PA8854001A1 (es) | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
| MX2011007681A (es) | 2009-01-19 | 2011-08-08 | Abbott Lab | Agentes inducidores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes. |
| CN104945311A (zh) * | 2009-01-19 | 2015-09-30 | Abbvie公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| TW201038569A (en) | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
| AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
| TWI519530B (zh) | 2009-02-20 | 2016-02-01 | 艾伯維德國有限及兩合公司 | 羰醯胺化合物及其作為鈣蛋白酶（ｃａｌｐａｉｎ）抑制劑之用途 |
| JP2012522004A (ja) | 2009-03-27 | 2012-09-20 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドである化合物 |
| WO2010111574A1 (en) * | 2009-03-27 | 2010-09-30 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
| EP2411370B1 (en) * | 2009-03-27 | 2015-04-22 | AbbVie Inc. | Compounds as cannabinoid receptor ligands |
| US8507493B2 (en) * | 2009-04-20 | 2013-08-13 | Abbvie Inc. | Amide and amidine derivatives and uses thereof |
| US8236798B2 (en) | 2009-05-07 | 2012-08-07 | Abbott Gmbh & Co. Kg | Carboxamide compounds and their use as calpain inhibitors |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| RU2535347C3 (ru) | 2009-05-26 | 2019-05-14 | ЭббВи Айэленд Анлимитед Компани | Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2010138828A2 (en) | 2009-05-29 | 2010-12-02 | Abbott Laboratories | Potassium channel modulators |
| WO2011053740A1 (en) | 2009-10-28 | 2011-05-05 | Belkin International, Inc. | Portable multi-media communication device protective carrier and method of manufacture therefor |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| MX2012006036A (es) | 2009-11-25 | 2012-06-19 | Abbott Lab | Moduladores del canal del calcio. |
| JPWO2011071135A1 (ja) | 2009-12-11 | 2013-04-22 | 塩野義製薬株式会社 | オキサジン誘導体 |
| TW201130855A (en) * | 2009-12-16 | 2011-09-16 | Abbott Lab | Prodrug compounds useful as cannabinoid ligands |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| NZ628298A (en) | 2010-03-25 | 2015-11-27 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| WO2011159785A1 (en) | 2010-06-15 | 2011-12-22 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
| US9132136B2 (en) * | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
| RU2013110324A (ru) | 2010-08-10 | 2014-09-20 | Эббви Инк. | Новые модуляторы trpv3 |
| US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9266855B2 (en) | 2010-09-27 | 2016-02-23 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| EP2634188A4 (en) | 2010-10-29 | 2014-05-07 | Shionogi & Co | FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE |
| EP2632436B1 (en) | 2010-10-29 | 2018-08-29 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| CA2816285A1 (en) | 2010-10-29 | 2012-05-03 | Shionogi & Co., Ltd. | Naphthyridine derivative |
| WO2012059431A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor |
| WO2012059432A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor |
| US8673950B2 (en) | 2010-11-02 | 2014-03-18 | Hoffmann-Laroche Inc. | Dihydrooxazol-2-amine derivatives |
| PE20140913A1 (es) | 2010-11-15 | 2014-08-22 | Abbvie Inc | Inhibidores de nampt y rock |
| CA2817093A1 (en) | 2010-11-15 | 2012-05-24 | Abbvie Inc. | Nampt inhibitors |
| US8609674B2 (en) | 2010-11-16 | 2013-12-17 | Abbvie Inc. | Potassium channel modulators |
| WO2012067822A1 (en) | 2010-11-16 | 2012-05-24 | Abbott Laboratories | Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators |
| WO2012071336A1 (en) | 2010-11-23 | 2012-05-31 | Abbott Laboratories | Salts and crystalline forms of an apoptosis-inducing agent |
| PT2642999T (pt) | 2010-11-23 | 2017-01-05 | Abbvie Ireland Unlimited Co | Métodos de tratamento que utilizam inibidores seletivos de bcl-2 |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US8802693B1 (en) | 2011-03-09 | 2014-08-12 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| US8802673B2 (en) | 2011-03-24 | 2014-08-12 | Hoffmann-La Roche Inc | Heterocyclic amine derivatives |
| US9012651B2 (en) | 2011-03-24 | 2015-04-21 | Abbvie Inc. | TRPV3 modulators |
| WO2012134943A1 (en) | 2011-03-25 | 2012-10-04 | Abbott Laboratories | Trpv1 antagonists |
| TW201247635A (en) | 2011-04-26 | 2012-12-01 | Shionogi & Co | Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them |
| US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| WO2012158399A1 (en) | 2011-05-13 | 2012-11-22 | Abbott Laboratories | Condensed 2 - carbamoylpyridazinones as potassium channel modulators |
| US9073911B2 (en) | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
| US9029370B2 (en) | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
| JP2014521682A (ja) | 2011-08-05 | 2014-08-28 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | アミノクロマン、アミノチオクロマンおよびアミノ−１，２，３，４−テトラヒドロキノリン誘導体、これらを含有する医薬組成物、ならびに治療におけるこれらの使用 |
| TWI561521B (en) | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI571466B (zh) | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
| US8772500B2 (en) | 2011-10-24 | 2014-07-08 | Abbvie Inc. | TRPV3 modulators |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| CN104011028A (zh) | 2011-11-18 | 2014-08-27 | 艾伯维德国有限责任两合公司 | N-取代的氨基苯并环庚烯、氨基四氢化萘、氨基茚满和苯烷基胺衍生物、包含所述衍生物的药物组合物及其在治疗中的用途 |
| WO2013096226A1 (en) | 2011-12-19 | 2013-06-27 | Abbvie Inc. | Trpv1 antagonists |
| WO2013096223A1 (en) | 2011-12-19 | 2013-06-27 | Abbvie Inc. | Trpv1 antagonists |
| EP2802578B1 (en) | 2012-01-12 | 2015-10-07 | F.Hoffmann-La Roche Ag | Heterocyclic derivatives as trace amine associated receptors (taars) |
| US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| WO2013149376A1 (en) | 2012-04-02 | 2013-10-10 | Abbott Laboratories | Chemokine receptor antagonists |
| CA2870931A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Isoindolone derivatives |
| TW201350481A (zh) | 2012-05-11 | 2013-12-16 | Abbvie Inc | Ｎａｍｐｔ抑制劑 |
| US9334264B2 (en) | 2012-05-11 | 2016-05-10 | Abbvie Inc. | NAMPT inhibitors |
| WO2013170113A1 (en) | 2012-05-11 | 2013-11-14 | Abbvie Inc. | Nampt inhibitors |
| US8975398B2 (en) | 2012-05-11 | 2015-03-10 | Abbvie Inc. | NAMPT inhibitors |
| US20130317054A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Neuronal nicotinic agonist and methods of use |
| US20130317055A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Neuronal nicotinic agonist and methods of use |
| WO2013185284A1 (en) | 2012-06-12 | 2013-12-19 | Abbott Laboratories | Pyridinone and pyridazinone derivatives |
| US8796328B2 (en) | 2012-06-20 | 2014-08-05 | Abbvie Inc. | TRPV1 antagonists |
| AU2013314279B2 (en) | 2012-09-14 | 2017-11-02 | AbbVie Deutschland GmbH & Co. KG | Tricyclic quinoline and quinoxaline derivatives |
| US20140080813A1 (en) | 2012-09-14 | 2014-03-20 | AbbVie Deutschland GmbH & Co. KG | Tricyclic quinoline and quinoxaline derivatives |
| ES2654653T3 (es) | 2012-09-14 | 2018-02-14 | F. Hoffmann-La Roche Ag | Derivados de pirazol-carboxamida como moduladores de TAAR para su uso en el tratamiento de varios trastornos, tales como depresión, diabetes y enfermedad de Parkinson |
| EP2895478B1 (en) | 2012-09-17 | 2016-10-19 | F. Hoffmann-La Roche AG | Triazole carboxamide derivatives |
| JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
| BR112015023013A2 (pt) | 2013-03-13 | 2017-07-18 | Abbvie Inc | inibidores de quinase cdk9 |
| AU2014244183A1 (en) | 2013-03-13 | 2015-08-13 | Abbvie Inc. | Pyridine CDK9 kinase inhibitors |
| EP2970258B1 (en) | 2013-03-14 | 2018-04-18 | AbbVie Deutschland GmbH & Co KG | Novel inhibitor compounds of phosphodiesterase type 10a |
| AU2014244194A1 (en) | 2013-03-14 | 2015-09-10 | Abbvie Inc. | Pyrrolopyrimindine CDK9 kinase inhibitors |
| UY35419A (es) | 2013-03-14 | 2014-10-31 | Abbvie Inc | Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina |
| CN105246890A (zh) | 2013-03-14 | 2016-01-13 | 艾伯维公司 | 吡咯并[2,3-b]吡啶cdk9激酶抑制剂 |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| MX2015012393A (es) | 2013-03-14 | 2016-04-28 | Abbvie Deutschland | Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina. |
| US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| MX2016004934A (es) | 2013-10-17 | 2016-12-20 | Abbvie Deutschland | Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia. |
| CN105992764A (zh) | 2013-10-17 | 2016-10-05 | 艾伯维德国有限责任两合公司 | 氨基色满、氨基硫代色满及氨基-1,2,3,4-四氢喹啉衍生物，包含其的药物组合物及其在治疗中的用途 |
| WO2015091931A1 (en) | 2013-12-20 | 2015-06-25 | AbbVie Deutschland GmbH & Co. KG | Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases |
| WO2015119712A1 (en) | 2014-02-06 | 2015-08-13 | Abbvie Inc. | Tetracyclic cdk9 kinase inhibitors |
| WO2015165085A1 (en) | 2014-04-30 | 2015-11-05 | F.Hoffmann-La Roche Ag | Morpholin-pyridine derivatives |
| BR112017000160A2 (pt) | 2014-08-27 | 2017-10-31 | Hoffmann La Roche | derivados de azetidina substituidos como ligantes de taar |
| WO2016030306A1 (en) | 2014-08-27 | 2016-03-03 | F. Hoffmann-La Roche Ag | Substituted pyrazino[2,1-a]isoquinoline derivatives for the treatment of cns disorders |
| US9617226B2 (en) | 2014-09-05 | 2017-04-11 | AbbVie Deutschland GmbH & Co. KG | Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases |
| US9550754B2 (en) | 2014-09-11 | 2017-01-24 | AbbVie Deutschland GmbH & Co. KG | 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy |
| WO2016160938A1 (en) | 2015-04-02 | 2016-10-06 | Abbvie Inc. | N-(1,3-thiazol-2-yl)pyrimidine-5-carboxamides as trpv3 modulators |
| WO2017089458A1 (en) | 2015-11-25 | 2017-06-01 | AbbVie Deutschland GmbH & Co. KG | Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders |
| PE20181446A1 (es) | 2016-03-17 | 2018-09-12 | Hoffmann La Roche | Derivados de 5-etil-4-metil-pirazol-3-carboxamida con actividad como de taar |
| US10858326B2 (en) | 2016-05-04 | 2020-12-08 | Purdue Pharma L.P. | Oxazoline pseudodimers, pharmaceutical compositions and the use thereof |
| DK3452484T3 (da) | 2016-05-07 | 2023-09-25 | Fochon Pharmaceuticals Ltd | Visse protein-kinase-inhibitorer |
| WO2017210616A1 (en) * | 2016-06-02 | 2017-12-07 | Purdue Pharma L.P. | Trace amine associated receptor 1 agonists and partial agonists for pain treatment |
| CN110139857B (zh) | 2016-11-28 | 2023-07-21 | 重庆复尚源创医药技术有限公司 | 作为吲哚胺2,3-双加氧酶抑制剂的亚砜亚胺、磺酰亚胺酰胺、磺酰二亚胺和二酰亚胺磺酰胺化合物 |
| EP3601255A1 (en) | 2017-03-21 | 2020-02-05 | AbbVie Deutschland GmbH & Co. KG | Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical |
| WO2018192462A1 (en) | 2017-04-18 | 2018-10-25 | Shanghai Fochon Pharmaceutical Co., Ltd. | Apoptosis-inducing agents |
| BR112020018444A2 (pt) | 2018-03-14 | 2020-12-29 | Fochon Pharmaceuticals, Ltd. | Compostos de (2-azabiciclo[3,1,0]hexan-2-il)pirazolo[1,5-a]pirimidina substituída e imidazo[1,2-b]piridazina como inibidores de trk cinases |
| US11485707B2 (en) | 2018-03-23 | 2022-11-01 | Fochon Pharmaceuticals, Ltd. | Deuterated compounds as rock inhibitors |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2731471A (en) * | 1956-01-17 | Nxg hi | ||
| FR6551E (fr) | 1905-07-27 | 1906-12-17 | Carlo Chiesa | Séchoir à tambour rotatif, démontable et transportable, et fonctionnant à ciel ouvert, pour cocons, céréales, etc. |
| US2161938A (en) * | 1934-07-31 | 1939-06-13 | Soc Of Chemical Ind | Imidazolines |
| US2457047A (en) * | 1946-02-13 | 1948-12-21 | Monsanto Chemicals | 2-(2'-thenyl)-4, 5-dihydroimidazoles and process for making the same |
| DE842065C (de) | 1950-07-30 | 1952-06-23 | Bayer Ag | Verfahren zur Herstellung stickstoffhaltiger heterocyclischer Verbindungen |
| US2778836A (en) * | 1954-04-02 | 1957-01-22 | Union Chimique Belge Sa | Substituted 2-methyl-delta2 imidazolines |
| US2744910A (en) * | 1955-06-27 | 1956-05-08 | Bristol Lab Inc | 2-(ortho-benzylbenzyl)-imidazoline and acid addition salts |
| US2744909A (en) * | 1955-06-27 | 1956-05-08 | Bristol Lab Inc | 2-(ortho-phenylbenzyl) imidazoline and acid addition salts |
| US2919274A (en) * | 1957-09-17 | 1959-12-29 | Sahyun Melville | Amidines |
| GB877306A (en) | 1958-04-21 | 1961-09-13 | Pfizer & Co C | Halogenated derivatives of tetrahydro-1-naphthyl cyclic amidines |
| DE1121054B (de) * | 1960-11-23 | 1962-01-04 | Merck Ag E | Verfahren zur Herstellung eines neuen Imidazolinderivates und dessen Saeureadditionssalzen |
| US3190802A (en) | 1961-10-09 | 1965-06-22 | Boehringer Sohn Ingelheim | Shaving composition and method of using same |
| FR1355049A (fr) | 1962-04-12 | 1964-03-13 | Merck Ag E | Agent pour le traitement préalable de la peau en vue du rasage |
| DE1150180B (de) * | 1962-04-12 | 1963-06-12 | Merck Ag E | Mittel zur Vorbehandlung der Haut fuer die Rasur |
| ES323985A1 (es) | 1966-02-26 | 1966-12-16 | Blade Pique Juan | Procedimiento para la obtenciën de derivados del imidazol |
| US3377247A (en) * | 1967-04-28 | 1968-04-09 | Dow Chemical Co | Antidepressant method |
| US3586695A (en) * | 1968-01-26 | 1971-06-22 | Dow Chemical Co | Substituted imidazolinyl indoles |
| US3577428A (en) * | 1969-04-14 | 1971-05-04 | Colgate Palmolive Co | 2-amino-4-aryloxyalkyl-4-alkyl-2-oxazolines |
| BE754820R (fr) | 1969-08-13 | 1971-02-15 | Schering Ag | Nouveaux derives de pyrimidine, leurs procedes de preparation et leurs |
| US3818094A (en) * | 1969-08-28 | 1974-06-18 | Boehringer Sohn Ingelheim | Hypotensive pharmaceutical compositions containing certain 2-anilino-1,3-diazacyclopentenes-(2) |
| US3622579A (en) * | 1969-08-28 | 1971-11-23 | Boehringer Sohn Ingelheim | Derivatives of 2-anilino-1,3-diazacyclopentene-(2) |
| US3660423A (en) * | 1970-02-13 | 1972-05-02 | Dow Chemical Co | 2-(substituted benzyl)methyl-2-imidazolines |
| GB1333471A (en) * | 1971-01-27 | 1973-10-10 | Labaz | Imidazoline derivatives and process for preparing the same |
| US3818476A (en) * | 1972-06-27 | 1974-06-18 | Tull Aviation Corp | Navigation aid transmitter-monitor system |
| DE2253555A1 (de) | 1972-11-02 | 1974-05-09 | Hoechst Ag | Oxazolo-pyrimidine und verfahren zu ihrer herstellung |
| US4125620A (en) * | 1974-10-01 | 1978-11-14 | Boehringer Ingelheim Gmbh | 2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof |
| DE2446758C3 (de) | 1974-10-01 | 1979-01-04 | C.H. Boehringer Sohn, 6507 Ingelheim | 2-(2-Fluor-6-trifluormethylphenylimino)-imidazolidin, dessen Säureadditionssalze, Verfahren zur Herstellung dieser Verbindungen und deren Verwendung bei der Bekämpfung der Hypertonie |
| US3992403A (en) * | 1975-05-30 | 1976-11-16 | Schering Corporation | 2-Imidazolines and their use as hypoglycemic agents |
| GB1538097A (en) * | 1976-01-26 | 1979-01-10 | Lafon Labor | Substituted phenyl-amidines |
| US4323570A (en) * | 1978-11-15 | 1982-04-06 | Beiersdorf Aktiengesellschaft | Substituted aminopyrimidines |
| DE2849537C2 (de) | 1978-11-15 | 1983-03-17 | Beiersdorf Ag, 2000 Hamburg | Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| SE431818C (sv) * | 1979-03-16 | 1985-04-29 | Turos Foodprocessing Ab | Forfarande for framstellning av crumbprodukter genom blandning av floden av mjolkravara, proteiner och reducerande socker |
| AU518569B2 (en) | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
| US4311840A (en) * | 1980-11-13 | 1982-01-19 | E. R. Squibb & Sons, Inc. | 2,3,6,7-Tetrahydro-2-thioxo-4H-oxazolo[3,2-a]-1,3,5 triazin-4-ones |
| PT77428B (fr) * | 1982-10-05 | 1986-02-27 | Cortial | Procede pour preparer de nouvelles amino-2-substitue-5-oxazoli-nes-2 et des compositions les contenant |
| US4540705A (en) | 1983-03-14 | 1985-09-10 | Sterling Drug Inc. | Antidepressant imidazolines and related compounds |
| DE3583900D1 (de) | 1984-06-06 | 1991-10-02 | Abbott Lab | Adrenergische verbindungen. |
| DK302185A (da) * | 1984-07-05 | 1986-01-06 | Rolland Sa A | 2-amino-oxazoliner samt fremgangsmaade til deres fremstilling |
| US4665095A (en) * | 1985-12-11 | 1987-05-12 | Abbott Laboratories | Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion |
| GB2215206B (en) | 1988-02-29 | 1991-07-03 | Farmos Oy | 4-substituted imidazole derivatives useful in perioperative care |
| FI894911A0 (fi) | 1989-10-17 | 1989-10-17 | Farmos Oy | En terapeutiskt vaerdefull foerening. |
| ES2245782T3 (es) | 1993-10-13 | 2006-01-16 | H. Joseph Horacek | Formula de clonidina de liberacion prolongada. |
| FR2726558B1 (fr) * | 1994-11-03 | 1996-12-06 | Adir | Nouvelles 5-(aryloxymethyl) oxazolines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| DE19514579A1 (de) * | 1995-04-20 | 1996-10-24 | Boehringer Ingelheim Kg | Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz |
| US5610174A (en) * | 1995-06-02 | 1997-03-11 | Synaptic Pharmaceutical Corporation | Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence |
| GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| US5969137A (en) | 1996-09-19 | 1999-10-19 | Virginia Commonwealth University | Benzylamidine derivatives with serotonin receptor binding activity |
| CA2229123A1 (en) | 1997-02-11 | 1998-08-11 | Mitchell Irvin Steinberg | Pharmaceutical agents |
| US5866579A (en) * | 1997-04-11 | 1999-02-02 | Synaptic Pharmaceutical Corporation | Imidazole and imidazoline derivatives and uses thereof |
| IL136388A0 (en) | 1997-12-04 | 2001-06-14 | Allergan Sales Inc | Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| WO1999032112A1 (en) | 1997-12-19 | 1999-07-01 | Eli Lilly And Company | Method for treating diabetes |
| ATE293102T1 (de) * | 1998-04-23 | 2005-04-15 | Takeda Pharmaceutical | Naphthalene derivate ,ihre herstellung und verwendung |
| ES2150378B1 (es) | 1998-08-07 | 2001-07-01 | Esteve Labor Dr | Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p. |
| CA2246027A1 (en) | 1998-08-27 | 2000-02-27 | Virginia Commonwealth University | Benzylamidine derivatives with serotonin receptor binding activity |
| DE19858593A1 (de) * | 1998-12-18 | 2000-06-21 | Merck Patent Gmbh | Sulfonyloxazolamine als therapeutische Wirkstoffe |
| PE20010781A1 (es) | 1999-10-22 | 2001-08-08 | Takeda Chemical Industries Ltd | Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion |
| JP2001302643A (ja) | 2000-04-21 | 2001-10-31 | Suntory Ltd | 環状アミジン化合物 |
| AU2001292617A1 (en) | 2000-09-12 | 2002-03-26 | Oregon Health And Science University | Mammalian receptor genes and uses |
| IL155436A0 (en) | 2000-11-14 | 2003-11-23 | Hoffmann La Roche | Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists |
| IL147921A0 (en) * | 2002-01-31 | 2002-08-14 | Abdulrazik Mohammad | A method for treating central nervous system disorders by ocular dosing |
| TW200306783A (en) | 2002-04-29 | 2003-12-01 | Fmc Corp | Pesticidal heterocycles |
| KR100492252B1 (ko) | 2002-08-09 | 2005-05-30 | 한국화학연구원 | 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법 |
| ATE405560T1 (de) * | 2002-11-25 | 2008-09-15 | Hoffmann La Roche | Indolderivaten |
| MXPA06001480A (es) | 2003-08-06 | 2006-05-15 | Pfizer Prod Inc | Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos. |
| CN101212898A (zh) | 2005-05-03 | 2008-07-02 | 拜尔农作物科学股份公司 | 杀虫的取代的氨基烷基杂环及杂芳基衍生物 |
| ATE517883T1 (de) | 2005-08-25 | 2011-08-15 | Schering Corp | Imidazolderivate als funktionelle selektive agonisten des alpha2c-adrenorezeptors |
| US20080146523A1 (en) | 2006-12-18 | 2008-06-19 | Guido Galley | Imidazole derivatives |
| JP5248528B2 (ja) | 2007-02-02 | 2013-07-31 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｎｓ疾患用のｔａａｒ１リガンドとしての新規２−アミノオキサゾリン |
-
2008
- 2008-02-05 MX MX2009008465A patent/MX2009008465A/es active IP Right Grant
- 2008-02-05 ES ES08708678.1T patent/ES2525229T3/es active Active
- 2008-02-05 WO PCT/EP2008/051377 patent/WO2008098857A1/en not_active Ceased
- 2008-02-05 CA CA2676944A patent/CA2676944C/en not_active Expired - Fee Related
- 2008-02-05 AU AU2008214774A patent/AU2008214774A1/en not_active Abandoned
- 2008-02-05 EP EP08708678.1A patent/EP2121641B1/en not_active Not-in-force
- 2008-02-05 KR KR1020127005517A patent/KR101335845B1/ko not_active Expired - Fee Related
- 2008-02-05 RU RU2009132189/04A patent/RU2460725C2/ru not_active IP Right Cessation
- 2008-02-05 BR BRPI0807813-0A patent/BRPI0807813A2/pt not_active IP Right Cessation
- 2008-02-05 KR KR1020097018132A patent/KR101222412B1/ko not_active Expired - Fee Related
- 2008-02-05 CN CN2008800053340A patent/CN101616902B/zh not_active Expired - Fee Related
- 2008-02-05 JP JP2009549394A patent/JP5130305B2/ja not_active Expired - Fee Related
- 2008-02-08 US US12/028,028 patent/US7902238B2/en not_active Expired - Fee Related
- 2008-02-12 CL CL200800434A patent/CL2008000434A1/es unknown
- 2008-02-12 TW TW097104905A patent/TWI372051B/zh not_active IP Right Cessation
- 2008-02-13 AR ARP080100608A patent/AR065322A1/es unknown
- 2008-02-13 PE PE2008000315A patent/PE20081783A1/es not_active Application Discontinuation
-
2009
- 2009-07-23 IL IL200045A patent/IL200045A0/en unknown
- 2009-07-28 ZA ZA200905272A patent/ZA200905272B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101616902A (zh) | 2009-12-30 |
| AU2008214774A1 (en) | 2008-08-21 |
| AR065322A1 (es) | 2009-05-27 |
| RU2009132189A (ru) | 2011-03-20 |
| ES2525229T3 (es) | 2014-12-19 |
| EP2121641B1 (en) | 2014-09-24 |
| BRPI0807813A2 (pt) | 2014-08-05 |
| CA2676944A1 (en) | 2008-08-21 |
| JP2010518137A (ja) | 2010-05-27 |
| EP2121641A1 (en) | 2009-11-25 |
| RU2460725C2 (ru) | 2012-09-10 |
| TW200845968A (en) | 2008-12-01 |
| US20090105307A1 (en) | 2009-04-23 |
| WO2008098857A1 (en) | 2008-08-21 |
| US7902238B2 (en) | 2011-03-08 |
| ZA200905272B (en) | 2010-05-26 |
| KR101335845B1 (ko) | 2013-12-02 |
| IL200045A0 (en) | 2010-04-15 |
| KR20120041776A (ko) | 2012-05-02 |
| MX2009008465A (es) | 2009-08-20 |
| TWI372051B (en) | 2012-09-11 |
| PE20081783A1 (es) | 2008-12-18 |
| KR20090104914A (ko) | 2009-10-06 |
| KR101222412B1 (ko) | 2013-01-15 |
| CN101616902B (zh) | 2013-03-27 |
| CA2676944C (en) | 2016-01-19 |
| JP5130305B2 (ja) | 2013-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008000434A1 (es) | Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros. | |
| CL2008001994A1 (es) | Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras. | |
| CL2008000690A1 (es) | Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras. | |
| CL2008000307A1 (es) | Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc. | |
| CL2007003879A1 (es) | Compuestos derivados de aril-carboxamida; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alzheimer, epilepsia y parkinson. | |
| CL2008002268A1 (es) | Compuestos derivados de amidas, moduladores del receptor taar1; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, entre otros. | |
| CL2007002610A1 (es) | Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras. | |
| CL2008000875A1 (es) | Compuestos derivados de imidazolidin-2-ona; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades tales como dislipidemia, diabetes, enfermedades inflamatorias, entre otras. | |
| CL2008001114A1 (es) | Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras. | |
| CL2007003765A1 (es) | Compuestos derivados de 2-oxo-4-hidroxi-benzotiazol; procesode preparacion; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, bronquitis, asma y bronquiectasias. | |
| SV2010003662A (es) | Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081 | |
| CL2007002708A1 (es) | Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros. | |
| CL2008001921A1 (es) | Compuestos derivados de heterociclos sustituidos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ictus, isquemia cerebral, alzheimer, dolor, entre otras. | |
| CL2008000192A1 (es) | Compuestos derivados de purina sustituidos; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo a transplantes, leucemias, diabetes, entre otras. | |
| CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
| CL2007003629A1 (es) | Compuestos heterociclicos aril-sustituidos, moduladores del receptor de cannabinoides tipo i (cb1); proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos metabolicos y trastornos cognitivos. | |
| CL2008000670A1 (es) | Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras. | |
| CL2008003593A1 (es) | Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer | |
| CL2008001215A1 (es) | Compuestos derivados de heterociclos nitrogenados condensados; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, dislipidemia, obesidad y alzheimer. | |
| CL2007003774A1 (es) | Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis. | |
| CL2007002996A1 (es) | Compuestos derivados de quinolina sustituido, moduladores de los receptores x del higado; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome coronario agudo, alzheimer, diabetes y aterosclerosis. | |
| CL2008001125A1 (es) | Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad. | |
| CL2007002593A1 (es) | Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer. | |
| CL2012001673A1 (es) | Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras. | |
| CL2009000990A1 (es) | Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras. |